Search
Nandrolone decanoate
go.drugbank.com/drugs/DB08804ApprovedIllicitInvestigationalNandrolone decanoate, also known as nandrolone caprinate, is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile … [A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesProducts: PARABOLIN RETARD 5 MG AMPUL, 2 ADET, DECA - DURABOLIN® 50 MGMetiamide
go.drugbank.com/drugs/DB08805ExperimentalMetiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.
Bopindolol
go.drugbank.com/drugs/DB08807ExperimentalBopindolol (INN) is an ester prodrug for the beta blocker [pindolol].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesDichloroacetic acid
go.drugbank.com/drugs/DB08809ApprovedInvestigationalWithdrawnA phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness. … DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market
Cinitapride
go.drugbank.com/drugs/DB08810InvestigationalCinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.
Mixtures: ROGASTRIL PLUS®, ROGASTRIL PLUS®Categories: Serotonin 5-HT1 Receptor Agonists, Serotonin 5-HT2 Receptor AntagonistsLurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. … Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: LURAP® 40, LURAP ® 80Hyaluronic acid
go.drugbank.com/drugs/DB08818ApprovedInvestigationalVet approvedA popular use of hyaluronic acid in recent years is cosmetic injection due to its ability to minimize the appearance of wrinkles and aging-related skin imperfections.[L32193] … Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan found in connective, epithelial, and neural tissues; it was first isolated in 1934.
Mixtures: SYSTANE HA SP SOLUCIÓN OFTÁLMICA, Vitamin C 15% (L- Ascorbic Acid)Categories: Compounds used in a research, industrial, or household settingIvacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigationalIvacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. … [L6841] Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamideDeferiprone
go.drugbank.com/drugs/DB08826ApprovedInvestigationalThalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. … Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 1,2-Dimethyl-3-hydroxypyrid-4-one, 3-Hydroxy-1,2-dimethyl-4(1H)-pyridoneLomitapide
go.drugbank.com/drugs/DB08827ApprovedLomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A InhibitorsSynonyms: 9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDE